Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf(®)), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaekers, Bram L. T., Wolff, Robert, van Giessen, Anoukh, Pouwels, Xavier, Fayter, Debra, Lang, Shona, Armstrong, Nigel, Worthy, Gill, Duffy, Steven, Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834593/
https://www.ncbi.nlm.nih.gov/pubmed/29177842
http://dx.doi.org/10.1007/s40273-017-0591-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834593/
https://www.ncbi.nlm.nih.gov/pubmed/29177842
http://dx.doi.org/10.1007/s40273-017-0591-4

Ejemplares similares